Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-04-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/9783527630943.CH16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.

  2009cited by this paper
• Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

  2009cited by this paper
• Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.

  2009cited by this paper
• Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors.

  2009cited by this paper
• Synthetic Strategies of Nonpeptidic β-Secretase (BACE1) Inhibitors

  2009cited by this paper
• Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.

  2009cited by this paper
• Progress toward the development of a viable BACE‐1 inhibitor

  2009cited by this paper
• Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.

  2009cited by this paper
• Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.

  2008cited by this paper
• Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.

  2008cited by this paper
• Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.

  2008cited by this paper
• BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells.

  2008cited by this paper
• BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.

  2008cited by this paper
• Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors.

  2008cited by this paper
• Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.

  2008cited by this paper
• Memapsin 2 (beta-secretase) inhibitors: drug development.

  2008cited by this paper
• BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).

  2008cited by this paper
• Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues.

  2008cited by this paper
• Progress toward a practical BACE-1 inhibitor.

  2007cited by this paper
• Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.

  2007cited by this paper
• Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase.

  2007cited by this paper
• Discovery of Isonicotinamide Derived β-Secretase Inhibitors: In Vivo Reduction of β-Amyloid

  2007cited by this paper
• Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors.

  2007cited by this paper
• Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo

  2007cited by this paper
• Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid.

  2007cited by this paper
• Design and Synthesis of 2,3,5‐Substituted Imidazolidin‐4‐one Inhibitors of BACE‐1

  2007cited by this paper
• Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1.

  2007cited by this paper
• Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation.

  2007cited by this paper
• Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

  2006cited by this paper
• Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex.

  2006cited by this paper
• Progress toward the discovery and development of efficacious BACE inhibitors.

  2006cited by this paper
• beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells.

  2006cited by this paper
• Conformationally biased P3 amide replacements of beta-secretase inhibitors.

  2006cited by this paper
• Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres.

  2006cited by this paper
• Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model.

  2006cited by this paper
• BACE-1 inhibition by a series of ψ[CH2NH] reduced amide isosteres

  2006cited by this paper
• The novel β‐secretase inhibitor KMI‐429 reduces amyloid β peptide production in amyloid precursor protein transgenic and wild‐type mice

  2006cited by this paper
• Synthesis of Indoles: Efficient Functionalization of the 7-Position.

  2006cited by this paper
• Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability.

  2005cited by this paper
• Structure-based design of cycloamide–urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase)

  2005cited by this paper
• Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases.

  2004cited by this paper
• Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

  2004cited by this paper
• Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.

  2004cited by this paper
• P3 cap modified Phe*-Ala series BACE inhibitors.

  2004cited by this paper
• Design and Synthesis of Hydroxyethylene-Based Peptidomimetic Inhibitors of Human β-Secretase

  2004cited by this paper
• In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitors

  2004cited by this paper
• Design and development of BACE-1 inhibitors.

  2004cited by this paper
• Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors.

  2004cited by this paper
• Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR.

  2004cited by this paper
• KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.

  2004cited by this paper
• Rational design and synthesis of selective BACE-1 inhibitors.

  2004cited by this paper
• Synthesis of potent β-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure–activity relationship studies

  2003cited by this paper
• KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides.

  2003cited by this paper
• Design and synthesis of statine-containing BACE inhibitors.

  2003cited by this paper
• Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase.

  2003cited by this paper
• Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity.

  2002cited by this paper
• Crystal Structure of Memapsin 2 (β-Secretase) in Complex with an Inhibitor OM00-3†

  2002cited by this paper
• Design of Substrate-Based Inhibitors of Human β-Secretase

  2002cited by this paper
• Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation

  2001cited by this paper
• The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

  2001cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase)

  2001cited by this paper
• Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design†

  2001cited by this paper
• BACE1 is the major β-secretase for generation of Aβ peptides by neurons

  2001cited by this paper
• The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.

  2000cited by this paper
• Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase).

  2000cited by this paper
• Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.

  2000cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Purification and cloning of amyloid precursor protein β-secretase from human brain

  1999cited by this paper
• Identification of a novel aspartic protease (Asp 2) as beta-secretase.

  1999cited by this paper
• Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

  1999cited by this paper

• Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands.

  2017cites this paper
• Highly Stereoselective Asymmetric Aldol Routes to tert-Butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building Blocks for Novel Protease Inhibitors.

  2017influential citation
• The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease

  2016cites this paper
• Structure-based Design of Drugs and Other Bioactive Molecules: Tools and Strategies

  2014cites this paper
• Iminoheterocycle as a druggable motif: BACE1 inhibitors and beyond.

  2012cites this paper